Clinical trial
A Phase 2 Pilot Study Assessing Immunogenicity and Safety of IC43 in Intensive Care Patients
NCT00876252 is registered in ClinicalTrials.gov with Valneva Austria GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Pilot Study Assessing Immunogenicity and Safety of IC43 in Intensive Care Patients
- Lead sponsor
- Valneva Austria GmbH
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2008
- Completion date
- February 28, 2010
- Enrollment
- 400 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.